Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction

PHASE2CompletedINTERVENTIONAL
Enrollment

294

Participants

Timeline

Start Date

July 7, 2022

Primary Completion Date

September 26, 2024

Study Completion Date

March 17, 2025

Conditions
Myocardial Infarction, AcuteHeart Failure, Left Sided
Interventions
DRUG

CDR132L

CDR132L is a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132). miR-132 in cardiomyocytes is a central switch affecting the expression of genes that are crucially involved in maladaptive cardiac remodeling, transformation, and pathological cardiac growth (hypertrophy), contributing to adverse cardiac remodeling and heart failure (HF).1-5 Aberrant expression of miR-132 in cardiac cells is causally associated with cardiac remodeling and HF progression.

DRUG

Placebo to CDR132L

Placebo to CDR132L

Trial Locations (49)

Unknown

Institut klinicke a experimentalni mediciny, Prague

Všeobecná fakultní nemocnice v Praze, Prague

St. Marien-Krankenhaus Ahaus, Ahaus

Herzzentrum Dresden Universitätsklinik, Dresden

Helios Klinikum Erfurt, Erfurt

Universitätsmedizin Göttingen, Göttingen

Medizinische Hochschule Hannover, Hanover

Universitätsklinikum Schleswig-Holstein, Kiel

Klinikum Ludwigshafen, Ludwigshafen

Universitätsklinikum Würzburg, Würzburg

"Alexandra General Hospital of Athens", Athens

"Attikon General University Hospital", Athens

"General University Hospital of Patras Panagia i Voitheia", Pátrai

Semmelweis University, Budapest

Jeroen Bosch Ziekenhuis (JBZ) (Hieronymus Bosch Hospital) - locatie Den Bosch, 's-Hertogenbosch

Deventer Ziekenhuis, Deventer

Slingeland Ziekenhuis, Doetinchem

Gelderse Vallei Ziekenhuis, Ede

Medisch Centrum Leeuwarden, Leeuwarden

St. Jansdal Ziekenhuis, Lelystad

Erasmus University Medical Center, Rotterdam

Ikazia Ziekenhuis, Rotterdam

D & A Research B.V., Sneek

Gelre Ziekenhuizen, Zutphen

Polsko Amerykanskie Kliniki Serca, Kędzierzyn-Koźle

Specjalistyczna Poradnia Kardiologiczna i Nadcisnienia Tetniczego, Kielce

Krakowski Szpital Specjalistyczny im. Jana Pawla II, Krakow

Gabinet Internistyczno-Kardiologiczny Jacek Nowak, Libiąż

NZOZ SALUS JZ Peruga, Lodz

One wojskowy Szpital Kliniczny w Lublinie, Lublin

Medicome Sp. z o.o., Oświęcim

Wojewódzki Szpital im. Sw. Ojca Pio w Przemyslu, Przemyśl

NZOZ Pro-Cordis Sopockie Centrum Bad. Kardiolog, Sopot

Wojewodzki Szpital Zespolony, Torun

Spec.Szpital im.dr Sokolowskiego, Wałbrzych

Investigational Site, Wroclaw

Hospital Universitari Germans Trias i Pujol, Badalona

Hospital de la Santa Creu I Sant Pau, Barcelona

Hospital Universitario San Cecilio, Granada

Hospital Universitario La Paz, Madrid

Hospital Universitario Virgen de la Arrixaca, Murcia

Hospital Universitario de Sabadell, Sabadell

Hospital Universitario Virgen Macarena, Seville

Hospital Clinico Universitario de Valencia, Valencia

Complejo Hospitalario Universitario de Vigo, Vigo

Queen Elizabeth University Hospital, Glasgow

Wycombe Hospital, High Wycombe

Richmond Pharmacology Limited, London

South Tees Hospital NHS Foundation Trust, Middlesbrough

Sponsors
All Listed Sponsors
lead

Cardior Pharmaceuticals GmbH

INDUSTRY